209 related articles for article (PubMed ID: 36640396)
1. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.
Burschinski A; Schneider-Thoma J; Chiocchia V; Schestag K; Wang D; Siafis S; Bighelli I; Wu H; Hansen WP; Priller J; Davis JM; Salanti G; Leucht S
World Psychiatry; 2023 Feb; 22(1):116-128. PubMed ID: 36640396
[TBL] [Abstract][Full Text] [Related]
2. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
Leucht S; Cipriani A; Spineli L; Mavridis D; Orey D; Richter F; Samara M; Barbui C; Engel RR; Geddes JR; Kissling W; Stapf MP; Lässig B; Salanti G; Davis JM
Lancet; 2013 Sep; 382(9896):951-62. PubMed ID: 23810019
[TBL] [Abstract][Full Text] [Related]
4. Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials.
Schneider-Thoma J; Kapfhammer A; Wang D; Bighelli I; Siafis S; Wu H; Hansen WP; Davis JM; Salanti G; Leucht S
Syst Rev; 2021 Aug; 10(1):214. PubMed ID: 34340713
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis.
Pillinger T; McCutcheon RA; Vano L; Mizuno Y; Arumuham A; Hindley G; Beck K; Natesan S; Efthimiou O; Cipriani A; Howes OD
Lancet Psychiatry; 2020 Jan; 7(1):64-77. PubMed ID: 31860457
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine for schizophrenia.
Duggan L; Fenton M; Rathbone J; Dardennes R; El-Dosoky A; Indran S
Cochrane Database Syst Rev; 2005 Apr; (2):CD001359. PubMed ID: 15846619
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine for schizophrenia.
Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
Cochrane Database Syst Rev; 2003; (1):CD001359. PubMed ID: 12535408
[TBL] [Abstract][Full Text] [Related]
8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine for schizophrenia.
Duggan L; Fenton M; Dardennes RM; El-Dosoky A; Indran S
Cochrane Database Syst Rev; 2000; (2):CD001359. PubMed ID: 10796640
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
13. Sertindole for schizophrenia.
Lewis R; Bagnall AM; Leitner M
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001715. PubMed ID: 16034864
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.
Schneider-Thoma J; Chalkou K; Dörries C; Bighelli I; Ceraso A; Huhn M; Siafis S; Davis JM; Cipriani A; Furukawa TA; Salanti G; Leucht S
Lancet; 2022 Feb; 399(10327):824-836. PubMed ID: 35219395
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; Bhoopathi PS; Kissling W; Leucht S
Cochrane Database Syst Rev; 2009 Oct; (4):CD006627. PubMed ID: 19821380
[TBL] [Abstract][Full Text] [Related]
16. Quetiapine versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; Srisurapanont M; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Jan; (1):CD006625. PubMed ID: 20091600
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
18. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
